WALTHAM, Mass. and DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of SLE did not show a statistically significant ...
DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage ...
Horizon Therapeutics plc HZNP announced that the phase II study evaluating its pipeline candidate, dazodalibep, for the treatment of Sjögren’s syndrome has met the primary endpoint in patients with ...
PARIS--(BUSINESS WIRE)--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of ...
WALTHAM, Mass. and DUBLIN, Oct. 27, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback